Neumirna Therapeutics ApS: Financial statements 2023
CVR: 41696451
Source: annual report 2023, Danish Business Authority
01/01/2023 – 31/12/2023
Neumirna Therapeutics ApS (CVR 41696451) has filed annual accounts for 2023. In 2023, the company reported a gross profit of DKK -5,476,181 and a net result of DKK -8,034,417 compared with DKK -5,292,246 the year before. Equity in the 2023 report amounted to DKK -11,467,952. The company had 3 employees in the financial year.
- Gross Profit
- DKK -5,476,181
- Profit/Loss
- DKK -8,034,417
- Equity
- DKK -11,467,952
- Total Assets
- DKK 6,254,894
- Employees
- 3
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | - | -5.5M | -8M | -11.5M | 3 |
| 2022 | - | -4.7M | -5.3M | -3.4M | 3 |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record, straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
As of November 1, 2023, Janine Terra Erler is registered as adm. dir. of Neumirna Therapeutics ApS.
As of November 1, 2023, Henrik Valdemar Klitgaard has stepped down as adm. dir. of Neumirna Therapeutics ApS.
Neumirna Therapeutics ApS has published its annual report for 2022. Gross profit came to DKK -4,660,603, and the net result was DKK -5,292,246.
As of January 2, 2023, Milla Koistinaho has joined the board of directors of Neumirna Therapeutics ApS.
About Neumirna Therapeutics ApS
Neumirna Therapeutics ApS is a Danish company of the type Anpartsselskab based in København SV, founded in 2020. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Ellen Kinson Donnelly. The board consists of Luis Garcia Pareras (chair), Andreas Wallnöfer, Ellen Kinson Donnelly and Francesco Paolo Di Giorgio. The company's owners include HELLERUNG ApS, INVIVO VENTURES III, FCRE and Innovestor Life Science Fund Ky. The company has 11 employees (2026). In 2025, the company reported a gross profit of DKK -53,859,865 and a net result of DKK -55,785,767 compared with DKK -6,954,201 the year before. Equity in the 2025 report amounted to DKK 91,816,175.